ALSO NOTED: Teva's Accupril gets FDA OK; Elder Pharmaceuticals buys Biomeda;

> Teva has nabbed an OK from the FDA for its generic form of Accupril, Pfizer's high blood pressure remedy. Total U.S. sales of the drug--branded and generic forms--amounted to $150 million for the 12 months ended June 30. Release

> Indian drug maker Elder Pharmaceuticals has agreed to buy Bulgaria's Biomeda Group for €10 million in cash. It's Elder's second acquisition in two months; the company hopes to use Biomeda as leverage for more European product launches. Report

> Medical laser-maker Candela got a new indication from the FDA for its Serenity device, used to reduce pain during pulsed-light and laser treatments. Report

And Finally... Low-dose products for menopause treatment have flooded the market with since the Women's Health Initiative found that hormone therapy could be harmful. But there's no research proving low doses are safer than traditional products. Article

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.